中國飛鶴(06186.HK)料未來兩年奶粉銷量斷崖式下跌 乳業股下挫
據內媒報道,中國飛鶴(06186.HK)董事長冷友斌出席論壇活動時表示,由於注射疫苗的影響,有很多父母在6個月內不能懷孕,預計奶粉銷量在未來一至兩年會出現斷崖式下跌,因此將在產品使用周期上進行大量科研投入和產品研發。
乳業股全線下挫,中國飛鶴現報19.46元,跌5.53%;原生態牧業(01431.HK)跌近4.92%,報0.58元;現代牧業(01117.HK)報1.79元,跌近4.28%;澳優(01717.HK)跌3.45%,現報11.18元;中國聖牧(01432.HK)報0.57元,跌1.72%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.